Prior to the last decade, hereditary cancer genomic testing comprised time‐consuming, sequential sequencing of high‐penetrance genes in cancer families to determine susceptibility, while precision genomic testing was limited to a handful of variants within specific cancers that could guide management (e.g. BRAF V600E) [1]. This evidence concerns the gene BRAF and cancer.